These are alternative splice variants of VEGF-A differing in exon 6 and 7 inclusion. VEGF121 (14 kDa homodimer) lacks heparin-binding domains and is freely diffusible. VEGF165 (23 kDa homodimer) retains exon 7, giving it moderate heparin binding and the ability to bind Neuropilin-1 — it is the most abundant and biologically potent isoform. VEGF189 retains both exons 6 and 7, binds heparin strongly, and is sequestered in the ECM. VEGF165 is the standard isoform for bioassays and therapeutic antibody screening.

Bevacizumab is a full-length humanized IgG1 anti-VEGF-A antibody (oncology, off-label ophthalmology). Ranibizumab is a humanized Fab fragment derived from the same parent antibody as Bevacizumab, optimized for intravitreal injection in AMD. Aflibercept is a VEGF trap — a recombinant fusion protein of VEGFR1 and VEGFR2 extracellular domains fused to IgG1 Fc, which binds VEGF-A, VEGF-B, and PlGF with very high affinity. Each has distinct binding epitopes, affinities, and target spectra.

The gold standard is a HUVEC (Human Umbilical Vein Endothelial Cell) proliferation assay. Seed HUVECs in low-serum medium, add serial dilutions of VEGF165, and measure proliferation after 72 hours by MTT, CellTiter-Glo, or BrdU incorporation. Bioactive VEGF165 should show an EC₅₀ of approximately 1-10 ng/mL. Alternative readouts include HUVEC tube formation on Matrigel and VEGFR2 phosphorylation (pY1175) by Western blot or ELISA.

VEGFR2 (KDR) is the primary signaling receptor for VEGF-A-driven angiogenesis — it mediates endothelial cell proliferation, survival, migration, and vascular permeability. VEGFR1 (Flt-1) has higher VEGF-A binding affinity (~10-fold over VEGFR2) but weaker kinase activity; it functions partly as a decoy receptor that modulates VEGFR2 signaling. Soluble VEGFR1 (sFlt-1) acts as an endogenous anti-angiogenic factor — elevated sFlt-1 in preeclampsia sequesters VEGF and causes endothelial dysfunction.

Yes. Elevated circulating VEGF has been associated with advanced tumor stage and poor prognosis in multiple cancers. Serum VEGF is also used as a pharmacodynamic biomarker during anti-VEGF therapy — effective treatment typically suppresses circulating free VEGF levels. Note: platelet degranulation during clotting releases stored VEGF, so plasma (EDTA) is preferred over serum for accurate VEGF measurement. Our ELISA kit is validated for both sample types.